

Regulation of p110 δ PI 3-Kinase Gene Expression

Klaartje Kok^{1,2}, Gemma E. Nock¹, Elizabeth A. G. Verrall^{1,‡}, Michael P. Mitchell³, Daan W. Hommes⁴, Maikel P. Peppelenbosch², Bart Vanhaesebroeck^{1*}

1 Centre for Cell Signalling, Institute of Cancer, Queen Mary University of London, Charterhouse Square, London, United Kingdom, **2** Department of Cell Biology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands, **3** Bioinformatics and Biostatistics, Cancer Research UK London Research Institute, London, United Kingdom, **4** Department of Gastroenterology and Hepatology; Leiden University Medical Centre, Leiden, The Netherlands

Abstract

Background: Despite an intense interest in the biological functions of the phosphoinositide 3-kinase (PI3K) signalling enzymes, little is known about the regulation of PI3K gene expression. This also applies to the leukocyte-enriched p110 δ catalytic subunit of PI3K, an enzyme that has attracted widespread interest because of its role in immunity and allergy.

Principal Findings: We show that p110 δ expression is mainly regulated at the transcriptional level. In fibroblasts, lymphocytes and myeloid cells, p110 δ gene transcription appears to be constitutive and not subject to acute stimulation. 5'RACE experiments revealed that p110 δ mRNA transcripts contain distinct upstream untranslated exons (named exon -1, -2a, -2b, -2c and -2d), which are located up to 81 kb upstream of the translational start codon in exon 1. The levels of all the different p110 δ transcripts are higher in leukocytes compared to non-leukocytes, with the p110 δ transcript containing exon -2a most abundantly expressed. We have identified a highly conserved transcription factor (TF) binding cluster in the p110 δ gene which has enhanced promoter activity in leukocytes compared to non-leukocytes. In human, this TF cluster is located immediately upstream of exon -2a whilst in mouse, it is located within exon -2a.

Conclusion: This study identifies a conserved *PIK3CD* promoter region that may account for the predominant leukocyte expression of p110 δ .

Citation: Kok K, Nock GE, Verrall EAG, Mitchell MP, Hommes DW, et al. (2009) Regulation of p110 δ PI 3-Kinase Gene Expression. PLoS ONE 4(4): e5145. doi:10.1371/journal.pone.0005145

Editor: Mikhail V. Blagosklonny, Ordway Research Institute, United States of America

Received: December 28, 2008; **Accepted:** February 19, 2009; **Published:** April 9, 2009

Copyright: © 2009 Kok et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Current and previous funding from Plamed, AstraZeneca and UCB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Personal support was from the AMC, Amsterdam, The Netherlands (KK), the Medical Research Council UK (EV, GEN) and the Ludwig Institute for Cancer Research (KK, GEN, EV, BV).

Competing Interests: Bart Vanhaesebroeck is an adviser to Intellikine, San Diego.

* E-mail: bart.vanh@qmul.ac.uk

‡ Deceased.

Introduction

Phosphoinositide 3-kinases (PI3Ks) generate lipid second messengers that regulate a broad variety of cellular responses such as growth, cell cycle progression, differentiation, vesicular traffic and cell migration [1]. PI3K activity is critical in a wide variety of normal and pathological physiological responses, including immune regulation, metabolic control and cancer. However, despite the importance of this signalling system, very little is known about the regulation of PI3K gene expression under normal and disease conditions.

The PI3K family is divided into 3 classes [2]. Class I PI3Ks are acutely activated upon receptor stimulation and are heterodimers consisting of a p110 catalytic subunit in complex with a regulatory subunit. The class I PI3Ks are further subdivided into class IA and IB, depending on whether the catalytic subunit is in complex with an SH2-domain containing regulatory subunit (collectively called 'p85') or with the p101 or p84 regulatory subunits, which lack SH2 domains. Mammals have 3 class IA p110 catalytic subunits, p110 α , p110 β and p110 δ , encoded by 3 distinct genes, *PIK3CA*, *PIK3CB* and *PIK3CD*, respectively. These p110 isoforms interact with p85, of which there are at least five different species, called p85 α , p55 α and p50 α (encoded by the *PIK3R1* gene) and p85 β

and p55 γ (encoded by *PIK3R2* and *PIK3R3*, respectively). p110 γ is the only class IB PI3K catalytic subunit and occurs in complex with p101 [3,4] or p84 [5,6], which have no homology to p85. Class I PI3Ks can be activated by tyrosine kinases (p110 α , p110 δ) or GPCRs (p110 β and p110 γ) [1,7–9].

Tissue distribution and the regulation of PI3K expression has recently been reviewed [10]. Whereas p110 α and p110 β appear to have a broad tissue distribution [11–15], p110 δ is highly expressed in leukocytes [12,13,16], found at intermediate levels in neurons [17] and present at low levels in most other cell types [13,18]. p110 δ is also expressed at moderate levels in some cancer cells of non-leukocyte origin such as melanoma and breast cancer cells, often with large differences in expression levels in cell lines of the same tissue origin [18], for reasons that are unclear at the moment. Like p110 δ , p110 γ is highly enriched in leukocytes [19–21] but is also found at lower levels in other cell types such as cardiomyocytes [22–24], endothelial cells [25], pancreatic islets [26,27] and smooth muscle cells [28].

Expression of the class IA catalytic isoforms can be altered during physiological and pathological processes, including differentiation (p110 α and p110 β) [29], regeneration (p110 α) [30,31] and hypertension (p110 β and p110 δ) [32–34]. PI3K expression, especially of p110 α , is also very frequently increased in cancer.

Insulin and nuclear receptor ligands can induce expression of the class I regulatory subunits [35–39]. Other documented mechanisms of p85 regulation are through the transcription factors (TF) STAT3 (p55 α and p50 α) [40], EBNA-2 (p55 α) [41] and SREBP (p55 γ) [42] and through targeted degradation of p85 α and p85 β by microRNAs [43,44] (reviewed in [10]).

Three recent studies have identified a transcription regulatory region for the human p110 α gene, *PIK3CA*. The *PIK3CA* locus gives rise to two alternative transcripts which each contain a distinct 5' untranslated exon (exon -1b or -1a) that is spliced onto the first translated (ATG-containing) exon. The genomic position of these 5' untranslated exons is about 50 kb upstream of the translation start site [45,46]. TF binding sites for p53 [45], FOXO3a [46] and NF- κ B [47] have been mapped in close proximity to the most 5' untranslated exon (called exon -1b). Whereas p53 might inhibit transcription of p110 α , evidence for a positive regulation by NF- κ B and FOXO3a has been presented.

A promoter region for murine p110 γ has also been identified [19]. Multiple transcriptional start sites exist for p110 γ , resulting in transcripts with varying 5' untranslated regions (5'UTRs), up to 874 bp in length. Analysis of the genomic p110 γ DNA up to 1.2 kb upstream from the transcription start site revealed that the putative promoter region contains consensus sites for housekeeping TFs such as API and SP1, as well as several putative binding sites for leukocyte-specific TFs [19]. Functional analysis of this p110 γ putative promoter region revealed enhanced promoter activity in the U937 myeloid cell line compared to the HeLa epithelial cell line [19].

In this study, we have investigated the regulation of p110 δ gene expression. We have documented that p110 δ protein expression largely correlates with the level of p110 δ mRNA in numerous cell types, indicating that p110 δ expression is predominantly regulated at the level of transcription. We have found multiple mouse and human p110 δ transcripts that contain distinct upstream untranslated exons, which we have named exon -1, -2a, -2b, -2c and -2d, located up to 81 kb upstream of the translational start codon in exon 1. Furthermore, we have identified a highly conserved TF-binding cluster that is located within mouse exon -2a and located immediately 5' upstream of human exon -2a. This TF-binding cluster has enhanced promoter activity in leukocytes compared to non-leukocytes. Out of the 7 different TF binding sites in the TF-binding cluster, 4 are associated with regulation of haematopoiesis and expression of leukocyte-specific genes. These findings are the first to identify a *PIK3CD* promoter and offer a rationale for the leukocyte-enriched expression of p110 δ .

Results

p110 δ protein expression is not altered in fibroblasts, B-lymphocytes and myelomonocytic cells upon acute stimulation with various agonists

We first investigated whether p110 δ expression can be induced by several acute cellular stimuli. In NIH-3T3 fibroblasts, which contain very low levels of endogenous p110 δ compared to leukocytes, p110 δ could not be induced by TNF, the proteasome inhibitor PS-341, UV irradiation, osmotic stress or the glucocorticoid dexamethasone (data not shown). p110 δ protein levels were also unaffected during different phases of the cell cycle in these cells (data not shown). In B lymphocytes, p110 δ expression was not affected by stimulation of the antigen receptor using anti-IgM antibodies. In U937 myelomonocytic cells, p110 δ levels were unaltered by treatment with retinoic acid, in contrast to the p110 γ protein which was induced effectively (data not shown), the latter in line with previously published data [48,49]. Taken together,

p110 δ expression appears not to be regulated in an acute manner in response to extracellular stimuli, at least in the cell types and conditions investigated.

Correlation between p110 δ mRNA and protein levels in cell lines

We next assessed the levels of p110 δ protein and mRNA, using immunoblotting of total cell lysates and real time RT-PCR, respectively, in a panel of murine and human cell lines (Figure 1A,B). p110 δ mRNA and protein were found in all cell lines investigated but in widely varying amounts. In line with published data [12,13,16,18], leukocytes expressed high levels of p110 δ while non-leukocytes expressed intermediate to low levels. In line with previous data [12], a good correlation was found between p110 δ mRNA and protein levels in most cell lines tested, indicating that p110 δ protein expression is mainly regulated at the level of transcription.

DNA methylation and histone acetylation are unlikely to be key mechanisms to control *PIK3CD* expression

DNA methylation and histone acetylation are important epigenetic mechanisms that control gene expression by dictating transitions between transcriptionally active or transcriptionally silent chromatin states [50,51]. L929 fibroblasts, which express low levels of p110 δ mRNA and protein, were treated with 5'-azacytidine or trichostatin A, agents known to cause DNA (hemi-) demethylation and histone hyperacetylation, respectively, creating open configurations of genomic DNA to allow binding of TFs. As a positive control, we monitored the previously documented induction in these cells of mRNA expression of the cytokines IL-6 and IFN- β by 5'-azacytidine and trichostatin A [52,53]. As can be seen from Figure 2, p110 δ mRNA expression levels were not dramatically altered by any of these treatments, with a maximum increase in p110 δ mRNA of around 2-fold, which was not accompanied by an induction of p110 δ protein expression.

The presence of high p110 δ mRNA levels is not a consequence of leukocyte-specific p110 δ mRNA stability

To assess whether high expression of the p110 δ protein in cells is due to increased mRNA stability, cells were treated with Actinomycin D, an inhibitor of *de novo* RNA synthesis, followed by measurement of mRNA decay over time. As can be seen from Figure 3A, leukocyte (A20 and EL4) and non-leukocyte (B16-BL6, 3LL and NIH-3T3) cell lines displayed very similar rates of mRNA degradation upon inhibition of mRNA synthesis, indicating that there is no difference in p110 δ mRNA stability between cell types expressing high or low levels of p110 δ protein. Also p110 δ protein levels were not affected by Actinomycin D treatment, both in leukocytes and non-leukocytes (Figure 3B).

Identification of multiple distinct p110 δ mRNA transcripts with alternate first 5' untranslated exons

In order to identify the *PIK3CD* promoter, we set out to identify the transcriptional start site of the p110 δ mRNA. Rapid amplification of 5' cDNA ends (5'RACE) was used to identify the 5'UTR. BLAT alignment of the 5'RACE products led to three main observations: (1) multiple distinct p110 δ transcripts exist within each cell line investigated; (2) most transcripts contains two untranslated exons (Figure 4A), which we have named exon -1 and -2 (to indicate their relative locations with respect to exon 1, which contains the putative ATG translation start site as defined in [13,54]). The -1 and -2 exons are located 11 kb and >35 kb 5' of exon 1 in murine cells, and 19 kb and >59 kb 5' of exon 1 in




Figure 1. Correlation between p110 δ protein and mRNA expression levels in murine and human cell lines. (A) Total cell lysates from the indicated cell lines were immunoblotted with antibodies to the distinct p110 isoforms or β -actin. One representative immunoblot of three independent experiments is shown. The bars represent quantification of the relative amounts of p110 δ protein in mouse and human cell lines, as determined in 3 independent experiments (for each cell line, the ratio of the OD of the p110 δ immunoblot signal was determined, relative to that of β -actin in this cell line. This value was then expressed relative to the p110 δ / β -actin ratio found in B16-BL6 (for the mouse lines) or HeLa (for the human lines). Values are averages of three independent experiments. (B) Quantification of p110 δ mRNA levels by real time RT-PCR using primers in the p110 δ coding region. Signals are normalised to β -actin mRNA in each cell line. Data shown are the averages of three independent experiments. doi:10.1371/journal.pone.0005145.g001

human cells; (3) exon -1 can occur together with one of 4 identified second untranslated exons (exons -2a, -2b, -2c or -2d) in mouse cells, and with one of two -2 exons (-2a or -2b) in human cells. Thus, mouse and human *PIK3CD* can give rise to at least 4 and 2, respectively, distinct p110 δ transcripts.

Human and mouse p110 δ exon 1 contains an in-frame stop codon immediately upstream of the p110 δ start codon (for sequences, see Supporting Information, File S1), ruling out the possibility that the newly identified upstream exons are translated as part of the p110 δ protein. In other words, the -1 and -2 exons form the 5'UTR of the *PIK3CD* transcripts.

The -1 exons identified in human and mouse show a high degree of homology (data not shown) and likewise the -2a exons share a region of high homology (Figure 4B). Human exon -2a

is approximately half the length of mouse exon -2a (72 bp compared to 144 bp), and its first part (1–49 bp) is homologous to the last part of mouse exon -2a (96–144 bp). Interestingly, the intronic DNA immediately upstream of human exon -2a is highly homologous with the first part of mouse exon -2a (Figure 4B). In contrast the -2b exons for human and mouse are not homologous, which may indicate that the -2b exon identified in human may not be the equivalent -2b exon identified in mouse.

Database information provides independent confirmation of several of the untranslated exons identified in this study (-1, -2a, -2b and -2c in the mouse; and -1, -2a in human), as well as additional -2 exons in the mouse (labeled with an arrowhead in Figure 4B) which we have thus far not found by 5'RACE both in




Figure 2. DNA methylation and histone acetylation do not alter p110 δ expression in mouse L929 fibroblasts. (Top panel) L929 cells were treated with 5'-azacytidine (5AC; 5 μ M) for 72 h and/or trichostatin A (TSA; 100 nM) for 6 h, with or without 6 h co-treatment with TNF (100 IU/ml). mRNA levels of p110 δ , IL-6 and IFN- β were quantified by real time RT-PCR. Samples were normalised for GAPDH and are relative to p110 δ mRNA amounts in the unstimulated samples (set as 1). Shown is the average of three independent experiments. (Lower panel) Representative immunoblot (of three) of p110 δ protein. doi:10.1371/journal.pone.0005145.g002

mouse and human (>50 independent 5'RACE products sequenced; detailed data not shown).

The p110 δ transcripts identified by 5'RACE always contained exon -1, and further incorporated a single -2 exon in all cases. We have found two instances where the -1/-2 exon of the p110 δ mRNA configuration does not seem to occur. Firstly, during the cDNA cloning of human p110 δ [13], we identified one clone (called o5) which did not contain exon -1, and which has exon -2a directly spliced onto exon 1, giving rise to a p110 δ transcript that encodes full length p110 δ protein (data not shown). Secondly, 2 out of 48 transcripts identified by 5'RACE in the mouse EL4 leukocyte cell line did not have -2 exons, and started with an exon -1. As shown in Table 1, all -2 and -1 exons contain a classical splice donor sequence (GT), whereas exon -1 only contains a splice acceptor sequence (AG). This is in line with the observation that each p110 δ transcript identified by 5'RACE contains a single -2 exon and further indicates that the different p110 δ transcripts arise individually and not from a 'master' p110 δ transcript by alternative splicing. The presence of a splice acceptor sequence in exon -1 indicates that the p110 δ transcript starting at this exon (as revealed by 5'RACE) found in mouse EL4 cells could in fact be an artefact, due to RNA degradation during the RACE experiments.

Cell type-specific usage of the multiple *PIK3CD* transcription start sites

We next used RT-PCR to confirm the presence of the different p110 δ transcripts identified by 5'RACE and to determine which of these can be found in a panel of murine leukocyte and non-leukocyte cell lines. Forward primers, specific for each of the 5' untranslated exons were designed, and used in combination with a common reverse primer in exon 2 (schematically shown in Figure 5A). PCR products of the predicted size were purified by




Figure 3. Equal p110 δ mRNA stability in leukocytes and non-leukocytes. The indicated cell lines were treated with Actinomycin D (4 μ g/ml), an inhibitor of *de novo* RNA synthesis, for the indicated time points followed by quantification of either p110 δ mRNA (A) or p110 δ protein (B). p110 δ mRNA was quantified by real time RT-PCR, using normalisation for 18S RNA. p110 δ mRNA levels are presented in a semi-log plot. doi:10.1371/journal.pone.0005145.g003

agarose gel electrophoresis and verified by DNA sequencing (data not shown).

All cell lines tested (except CT26 colon carcinoma) expressed at least one type of transcript containing a -2 exon (Figure 5B). Leukocytes contained a broader variety of p110 δ transcripts than non-leukocytes, with an average number of distinct p110 δ transcripts of 4.3 *versus* 2.4 in leukocytes and non-leukocytes, respectively (summarized in bottom panel of Figure 5B).

To more accurately quantify the amount of each p110 δ transcript, we next used real time RT-PCR (Figure 6). For each transcript, the PCR reaction consisted of a forward and reverse primer, which were designed to amplify a cDNA sequence of ~100 bp spanning an exon boundary specific to the transcript, and a dye-emitting probe, which bound at a sequence overlaying this exon boundary. During amplification of the cDNA sequence, cleavage of a reporter dye from the probe results in fluorescence emission, which can be directly correlated with the level of each particular p110 δ transcript. For example, to measure the amount of p110 δ transcripts containing exon -2a, a PCR was performed using a forward primer in exon -2a and a reverse primer in exon -




Figure 4. PIK3CD transcripts, assessed by 5'RACE and database analysis. (A) Top panel, Schematic representation of the different p110 δ mRNA transcripts in their genomic context as found by 5'RACE in murine and human cell lines. Bottom panel, the different p110 δ transcripts as found in the Ensembl database (release 52, 9 December 2008) for both species. Arrowheads indicate -2 exons present in the database which we have not found by 5'RACE. Asterisks indicate short *PIK3CD* transcripts (which do not encode full length p110 δ protein) found in the Ensembl database. (B) Region of homology between mouse and human exon -2a. Exons 1 which contain the transcription start sites are indicated with a vertical arrow. doi:10.1371/journal.pone.0005145.g004

1, while the dye-emitting probe bound at this exon-exon boundary. The fluorescence detected from this PCR reaction therefore represents the amount of all transcripts specifically containing exons -2a and -1.

These experiments revealed that leukocytes express significantly higher amounts of the different p110 δ transcripts than non-leukocytes (Figure 6), indicating that leukocytes are likely to be more efficient at using p110 δ gene promoters than non-leukocytes.

In all cell lines, the transcript containing the first coding exon (exon 1; Figure 6A) was expressed at similar levels as the transcript containing the exon -2a/exon -1 boundary, which is the most abundantly expressed -2 exon (Figure 6C).

Surprisingly, the transcripts containing the exon -1/exon 1 boundary (Figure 6B) were two-fold more abundant than the transcripts containing the exon 1/exon 2 boundary (Figure 6A). This indicates that shorter but still fully processed mRNAs (i.e. with a poly A tail since oligo d(T) was used for reverse transcription) are made. These would contain a 5'UTR with at least the untranslated exon -1 and the coding exon 1, but without any of the other coding exons. Database analysis also provided evidence for such shorter p110 δ transcripts (marked with asterisks in Figure 4A). These may belong to the recently identified new class of mRNA transcripts that initiate near the expected transcription start sites, upstream of protein encoding sequences [55–59].

In silico analysis of *PIK3CD* promoter

Alignment of the genomic sequence of flanking (and including) the 5'UTR exons of mouse *PIK3CD* with 8 other species revealed

high homology in specific areas, indicative for functionally conserved DNA sequences, including 4 CpG islands but no TATA boxes (Figure 7A; Supporting information, File S2).

For each of the murine untranslated exons, the region spanning 500 bp upstream and 100 bp downstream of the first nucleotide were analysed for TF-binding sites and the transcription start site (TSS) prediction score within this region was assessed (Figure 7B). TF-binding sites were identified in the vicinity of all mouse untranslated exons, however a particularly condensed cluster of TF-binding sites was identified *within* exon -2a (Figure 7B, C). Interestingly, in human, this TF-binding cluster lies 5' of the TSS (Figure 7C; schematically shown in Figure 7D). It is unusual, but not unheard of, that promoter regions are contained *within* exons. Indeed, recent work from the ENCODE project (<http://www.genome.gov/10005107> and <http://genome.cse.ucsc.edu/ENCODE/>) has revealed that proximal TF binding sites usually fall within 1 kb of both sides, 5' and 3', of the transcription start site [60].

The TF-binding cluster of murine exon -2a was located within a CpG island (Figure 7A); was associated with a good TSS prediction score (0.9/1.0; Figure 7B) and was highly conserved across 28 species (Supporting information, File S2; Figure 7C shows the high degree homology of this region across 8 species, Figure 7D schematically shows the homology between human and mouse in this area). Collectively, these observations indicate the presence of a putative promoter region in/around exon -2a. Interestingly, 4 of the 7 different TFs identified within this binding cluster, namely ETS, IRF, NFAT and LEF (indicated by an

Table 1. Splice donor and acceptor sites in the 5' introns/exons of *PIK3CD*.

| Human | | | | | | |
|-------------------------------------------------------------------------------------------|-----------|-----------------|-------------|-------------|------------------|-------------|
| Exon | Size (bp) | Splice acceptor | 5' end exon | 3' end exon | Splice donor | Intron (bp) |
| -2b | 251 | cgggggtca | GAGGCGCCCA | ACTCTGACAG | gtgagtcta | 61,243 |
| -2a | 59 | gcgccagc | GCAGTCGCTC | CGCCGGGACG | gtaagcgat | 39,665 |
| -1 | 105 | ccccaacag | ATAAGGAGTC | TTCCAGAGAG | gtaggttgg | 18,852 |
| 1 | 173 | catttttag | GACAAGTGC | CATCAAGCAG | gtatggcct | 4,944 |
| 2 | 229 | tcctccag | CTGCTGTGGC | ATCGGCAAAG | gtagtctg | |
| Uppercase letters represent exon sequences, lowercase letters represent intron sequences. | | | | | | |
| Murine | | | | | | |
| Exon | Size (bp) | Splice acceptor | 5' end exon | 3' end exon | Splice donor | Intron (bp) |
| -2d | 150 | ctccgggc | TAGGACTTCT | GGAGCAGTTC | gttttatta | 28,348 |
| -2c | 78 | gagagaga | ATCAGAAACC | CTACTCAAAT | gtcagattt | 28,270 |
| -2b | 117 | ttgagcgt | AAGAAAGCAG | ATGTAGAAGT | gtaagccaa | 27,309 |
| -2a | 144 | gttgtttt | CCTGTTATCT | TGCTGGACCG | gtaagtgtc | 24,360 |
| -1 | 119 | ttctttcag | ACATCTAAGG | TACCAAACAG | gtaggttgg | 10,759 |
| 1 | 173 | ttcccacag | GAAAACAGAC | CATCAAGCAG | gtagagcca | 2,913 |
| 2 | 229 | ctctccag | GTGCTGTGGC | ATTGCAAAG | gtatactta | |
| Uppercase letters represent exon sequences, lowercase letters represent intron sequences. | | | | | | |

Splice donor and acceptor sites in p110 δ exons. Splice acceptor and splice donor sequences of human (**top panel**) and murine (**lower panel**) p110 δ exons. The untranslated exons as well as exons 1 and 2 are represented. Uppercase letters represent exon sequences, lowercase letters represent intron sequences. AG/GT splice donor/acceptor sequences are in bold. All other coding exons of p110 δ follow the same AG/GT splicing rule (not shown).

doi:10.1371/journal.pone.0005145.t001

asterisk in Figure 7C), have previously been associated with haematopoiesis and expression of leukocyte-specific genes (discussed in more detail below), suggesting that this TF-binding region may be involved in the high p110 δ expression in leukocytes.

Functional analysis of putative *PIK3CD* promoter elements using reporter assays

We next cloned intronic genomic DNA sequences that flank mouse exons 1, -2a and -2b (including exons -2c and -2d) at their 5' end (Figure 7A,B; referred to as DNA fragments A–I) as well as mouse exon -2a itself (Figure 7B, DNA fragment J, which contains the TF-binding cluster), into the pGL3 reporter vector to drive expression of firefly *luciferase*. Vectors were transiently transfected in leukocyte and non-leukocyte cell lines and the promoter activities of the different *PIK3CD* DNA fragments were compared to that of the established leukocyte-specific promoter of Vav [61], and of the SV40 promoter, which is active in all cell types. The pGL3-Basic vector, which does not contain a promoter sequence upstream of firefly *luciferase*, was used to assess the basal level of luminescence.

The intronic genomic DNA fragments A–I did not possess significantly higher promoter activity in A20 leukocytes compared to NIH 3T3 fibroblasts (Figure 8B). This is in contrast to DNA fragment J (mouse exon-2a containing the TF-binding cluster) which had significantly higher promoter activity in the mouse macrophage cell line RAW 264.7 than in NIH 3T3 fibroblasts (Figure 8C), which was significantly higher than the leukocyte-specific *Vav* promoter (Figure 8C). The exon -2 fragment has also higher activity in the THP-1 monocytic cell line compared to the HEK293 (embryonic kidney) and CT26 (colon carcinoma) cell lines, again with higher activity compared to the *Vav* promoter (Figure 8C). Taken together with the relatively high abundance of the -2a transcripts (Figure 6C) over the other p110 δ exon -2 transcripts (Figure 6D–F), these data indicate that the TF binding cluster of exon -2a is the predominant promoter of p110 δ expression in leukocytes.

Discussion

In this study, we have explored the mechanisms by which the well-documented leukocyte-enriched expression of p110 δ might be




Figure 5. *PIK3CD* transcripts in murine cell lines and tissues, as assessed by RT-PCR (A) Schematic representation of PCR primers used to detect distinct murine *PIK3CD* transcripts. In each case, a reverse primer in exon 2 and a forward primer in exon 1, -1, -2a, -2b, -2c or -2d, was used. (B) Agarose gel analysis of PCR products generated by RT-PCR (40 cycles) using primers for the different p110δ mRNA transcripts in panel of murine cell lines and tissues, with the observations summarized underneath. doi:10.1371/journal.pone.0005145.g005

achieved. We present evidence that p110δ expression is mainly regulated at the transcriptional level arising from different transcripts. *PIK3CD* transcription appears to be constitutive and not responsive to acute cellular stimuli, at least using the agonists tested in the three cell types (NIH 3T3 and L929 fibroblasts, primary B cells and U937 myelomonocytic cells) used in our study. All cell types can express the distinct p110δ mRNA transcripts but leukocytes express a greater diversity of transcripts and significantly higher amounts of the individual transcripts. In particular, the p110δ transcript containing the untranslated exon -2a, was expressed at similar levels to the transcript containing coding exon 1 in a panel of murine leukocyte cell lines (compare Figure 6A with Figure 6C), indicating that the majority of p110δ transcripts in a cell contain exon -2a.

We have identified a region within mouse exon -2a that contains a cluster of TF-binding sites. This TF-binding cluster is highly conserved between species and found immediately upstream of human exon -2a in human. This TF binding cluster contains at least 4 leukocyte-related TFs sites and was found to display higher promoter activity in leukocyte cell lines compared to non-leukocyte cell lines. Given that the majority of *PIK3CD* transcripts contain exon -2a, these data indicate that the promoter region identified within mouse exon -2a is likely to be sufficient in mediating the majority of leukocyte-specific *PIK3CD* gene expression.

4 of the 7 TFs identified within this binding cluster, namely ETS, IRF, NFAT and LEF have previously been associated with

regulation of haematopoiesis and expression of leukocyte-specific genes. Indeed, the ETS family of TFs play important roles in the regulation of haematopoiesis [62–68]. IRF family members are highly expressed, but not exclusively, in cells of the immune system and play a pivotal role in the induction of type I IFN signalling pathways [69], proinflammatory cytokines and expression of macrophage and B cell specific genes [69,70]. NFAT family proteins are also mainly found in cells of the immune system, such as T cells, mast cells, NK cells and monocytes [71] and play a role in the regulation of various cytokines [72]. Finally, the LEF family of TFs, which are highly expressed in pre-B and T lymphocytes [73], have been linked to the regulation and expression of a number of lymphoid-specific genes [74–79].

High expression levels of p110δ are also frequently observed in some non-leukocyte cancer cell lines, such as in breast carcinoma, melanoma and glioma [18]. It is possible that cancer cells upregulate or aberrantly express TFs which are, in non-cancer cells, more specific for leukocytes. It is of interest to note that a number of the TFs that bind in the exon -2a cluster have indeed been implicated in breast cancer progression, including LEF [80–83], ETS-1 [84,85], ETS-2 [86] and NFAT3 [87]. Recently, all four of these leukocyte-associated TF were identified as the most frequently differentially activated TFs in breast cancer based on a large microarray dataset [88].

We have found evidence that, among the multiple p110δ transcripts, there may be mRNAs that do not encode full length p110δ. Indeed, transcripts containing the exon -1/exon 1




Figure 6. *PIK3CD* transcripts in murine cell lines, as determined by real time PCR. Absolute quantification of the different p110 δ transcripts in a panel of murine cell lines by real time RT-PCR (3 experiments) using primer mixes containing a forward primer in the first exon of each transcript, a reverse primer in the subsequent exon and a probe overlaying the exon/exon boundary. Copy numbers were calculated using a standard curve with the different transcripts cloned into a plasmid, and used as a control template for PCR. Samples were normalized to the levels of β -actin mRNA. The different panels represent amplification of the boundaries of (A) exon 1/exon 2; (B) exon -1/exon 1; (C) exon -2a/exon -1 (D) exon -2b/exon -1 (E) exon -2c/exon -1 (F) exon -2d/exon -1. doi:10.1371/journal.pone.0005145.g006

boundary are more abundant than those covering the exon 1/exon 2 boundary (compare Figure 6B to Figure 6A). Current database information supports the presence of such shorter p110 δ transcripts (marked with an asterisk in Figure 4A). Indeed, several recent studies have reported the discovery of a new class of short promoter-associated RNA transcripts that initiate near the expected transcription start sites upstream of protein-encoding sequences [56–58] (reviewed in [55]). It remains to be seen whether these RNAs have a function, but their prevalence suggests that their synthesis may serve a functional role.

Further work is required to understand the precise mechanism of p110 δ gene expression. The complexity of gene regulation has been exemplified by examination of 400 protein-coding genes in 1% (30 million bases) of the human genome as part of the ENCODE project [60], which revealed that 80% of these genes had additional exons, many of which were located thousands of bases away from the coding exons. Also many novel transcription start sites were found, many located thousands of bases away from the known start sites, while 25% of the promoters discovered were at the 3' end of the genes rather than at the 5' end. It is therefore highly likely that p110 δ expression will be subject to additional levels of control rather than by simple proximal promoter elements.

The data presented are the first to shed light onto the leukocyte-enriched expression of *PIK3CD*. Further investigations are needed to identify which TF-binding sites are critical in driving *PIK3CD* gene expression and whether cells of non-leukocyte origin, such as breast cancer cells, are able to utilize this putative promoter.

Interference with *PIK3CD* expression at the promoter level may offer a novel therapeutic target in cases of aberrant p110 δ overexpression, as observed in some cancers [18].

Materials and Methods

Antibodies and reagents

Antibodies to class IA PI3Ks were generated in-house or purchased from Santa Cruz Biotechnology (p110 β , sc-602). Cell culture reagents were purchased from Invitrogen, recombinant mouse TNF was provided by Peter Brouckaert (Ghent University, Belgium), other reagents were from Sigma: Actinomycin D (856258), 5'-azacytidine (A2358), trichostatin A (T8552), antibodies to β -actin (A5441).

RNA extraction, 5'Rapid Amplification of cDNA Ends (5'RACE), Reverse Transcription (RT)-Polymerase Chain Reaction (PCR) and Real Time RT-PCR

Total RNA was extracted from cells using the RNeasy mini kit (Qiagen, 74104). mRNA was subsequently reverse transcribed using SuperScript II Reverse Transcriptase (Invitrogen, 18064) and oligo d(T) primers, and subsequently used in 5'RACE, RT-PCR or real time PCR.

For 5'RACE, the FirstChoice[®] RLM-RACE kit (Ambion, 1700) was used following the manufacturer's protocol using the following outer primers: murine 5'-CAGATCAGCTCCTCA-TTGGCACT-3', human 5'-GCTTCTTCACGCGGTGCGCC-3' and inner primers: murine 5'-ACTTGAACCTCCCGTG-




Figure 7. Bioinformatic analysis of potential promoter elements and TF binding sites in *PIK3CD*. (A) Schematic representation of the murine p110 δ 5'UTR. The upper panel shows the five untranslated murine p110 δ exons (and exon 1) in their genomic context, with below (in descending order): the mouse RefSeq genes, CpG islands, homology with 9 species (rat, human, chimp, rhesus, dog, cow, armadillo, elephant, tenrec, plotted against the murine sequence) and the genomic fragments that were subcloned for use in gene reporter assays. (B) Locations of the conserved TF binding sites in the 600 bases (500 upstream to 100 downstream of the transcript start site) in the forward strand flanking the different 5' untranslated exons of mouse p110 δ gene. The exon start sites are indicated by the vertical arrows, the TF binding sites found on the forward strand are shown as blue boxes above the TSS score graphs. Also shown is the degree of cross species (28 species) genomic conservation as calculated by the phastCons program [94] from a minimum of 0.0 to a maximum of 1.0. The genomic DNA fragments subcloned into the PGL3 reporter vector are shown underneath. (C) Alignment and conservation of the TF binding cluster identified in mouse exon -2a with genomic sequences upstream of the translation start site of *PIK3CD* of 7 other species. (D) Schematic representation of TF binding cluster location in relation to exon -2 in human and mouse.

doi:10.1371/journal.pone.0005145.g007

TCCCG-3', human 5'-CGGGACACAGGGAAGTTCAGGT-3'. Products were cloned into pGEM-Teasy (Promega) for sequencing. RT-PCR for mouse p110 δ was carried out using a common reverse primer in exon 2 (5'-TGCCAATGAGGAGGCTGATCTG-3') in combination with exon-specific forward primers, as follows: for exon 1: 5'-CGTGGTTGTTGACTTCTTGC-3'; for exon -1: 5'-GAGAGCCAGGCAGAAGTGGGAT-3'; for exon -2a: 5'-GAAGTGGAGTGTGCGGACTGTG-3'; for exon -2b: 5'-GCATCAACTCCTGCCCTGTGTG-3'; for exon -2c: 5'-GCCATGCTATCGGGAACCTTGAG-3'; for exon -2d: 5'-CAGAGTGCTTCCGGTGGTATCC-3'. For RT-PCR of human p110 δ , the following primers were used: common reverse primer in exon 1: 5'-CGGGACACAGGGAAGTTCAGGT-3' in combination with the following exon-specific primers: for exon -1: 5'-TAAGGAGTCAGGCCAGGGCGG-3', for exon -2a: 5'-AGTTCGCTCCGAGCGGCCGCG-3', for exon -2b: 5'-CGAGGTTGGGAGAGGAGTGTG-3'. RT-PCR products were cloned into pGEM-Teasy vector (Promega) and sequenced using the T7 primer.

For real time RT-PCR amplification TaqMan Universal PCR Mastermix (4304437) and primer mixes containing a FAM reporter probe (TagMan Gene Expression Assay) were obtained from Applied Biosystems. SYBR Green (Qjagen, 204143) was used for quantifying 18S RNA. Exon-specific primer sets and probes were designed to identify transcripts containing exon -1, -2a, -2c and -2d. For exon -2a the following primer sequences were used; forward primer 5'-TCGCGCCTAGCCTTGG-3', reverse primer 5'-GGCATCAGCGGGCTTCA-3' and FAM reporter sequence 5'CTCAGCTCCTTAGATGTGCGGTC-3'. For exon -2b the following primer sequences were used; forward primer 5'-AGTGTCTGTCTGACTTCCTAAGAA-3', reverse primer 5'-CGGGCTTCATCCCCTTCTG-3' and FAM reporter sequence 5'-CAGCTCCTTAGATGTACTTCTACA-3'. For each transcript of interest, known amounts of plasmids with this transcript were used to create a standard curve. Real-time PCR generated a series of C_T values (the PCR cycle at which amplification of each target gene is first detected) for endogenous and plasmid-born cDNA, which allowed for




Figure 8. *PIK3CD* promoter analysis by reporter gene assays. (A) Schematic representation of the genomic *PIK3CD* DNA fragments (A–I) cloned upstream of firefly *luciferase* in the pGL3 reporter vector. (B) Promoter activity of each of the potential promoter regions (A–I) in A20 leukocytes and NIH-3T3 fibroblasts, as determined by luciferase reporter assays. The promoter activity of each *PIK3CD* region and the *Vav* promoter are expressed as a percentage of the SV40 promoter activity after subtraction of basal luminescence. (C) Promoter activity of mouse *PIK3CD* exon -2a DNA in leukocytes (RAW 264.7 and THP-1) versus non-leukocyte cell lines (NIH 3T3, HEK 293, and CT26), in two independent experiments. The promoter activity of exon -2a and *Vav* promoter are expressed as a percentage of the SV40 promoter activity after subtraction of basal luminescence. Each transfection was carried out in triplicate with the error bars indicating the standard deviation. doi:10.1371/journal.pone.0005145.g008

the determination of mRNA copy numbers for each individual gene.

Western blot

Cells were lysed and immunoblotted for PI3K expression as described before [89]. Primary antibodies were detected using fluorescently-labeled species-specific secondary antibodies (anti-mouse IRDye 800-conjugated (Rockland) and anti-rabbit Alexa-Fluor 680-conjugated (Molecular Probes). Quantification was done using an Odyssey infrared scanner (LICOR) using the manufacturer's software. Signal intensities were normalized for an internal loading control such as β -actin or GAPDH.

Bioinformatic analysis of putative promoter elements in *PIK3CD* genes

The upstream sequences for the five untranslated exons of the murine p110 δ gene were inspected within the February 2006 (NCBI build 36) assembly of the Mouse genome using the UCSC genome browser [90]. Regions spanning 500 bp upstream and 100 bp downstream of the first nucleotide of each exon were analysed. The corresponding multiple species alignment was extracted using the Vertebrate Multiz Alignment & Conservation

track [91] within the UCSC genome browser. The alignments were then screened for conserved TF binding sites using MatInspector [92] and a vertebrate factors subset of a proprietary database of Genomatix. In addition the candidate regions were inspected with Eponine [93], a probabilistic method for detecting transcription start sites, using a threshold of 0.9.

Reporter gene assays

PCR amplification of genomic DNA from C57Bl/6 mice was used to generate fragments for the reporter assays. The amplified PCR products were inserted into the pGL3 reporter vector (Promega). Transfections of NIH3T3 and A20 cells were performed using Qiagen Superfect or electroporation, respectively. Equal number of cells were washed and lysed, using Promega lysis buffer (to normalize for transfection efficiency) and then assayed for luciferase activity using the firefly luciferase substrate from Promega on the MicroBeta workstation (Perkin Elmer). The luciferase activity was normalized using a luciferase gene in a pGL3 reporter vector under the control of the SV40 promoter as well as a promoterless luciferase/pGL3 reporter vector. DNA of the lymphocyte-specific *Vav* promoter (construct HS21 mentioned in Ref. [61], which we cloned from the original β -galactosidase

reporter construct into a pGL2 luciferase reporter vector) was used as a positive control.

Supporting Information

File S1 5' RACE product sequences Sequences of the different murine (Mm) and human (Hs) p110 δ transcripts as identified by 5'RACE.

Found at: doi:10.1371/journal.pone.0005145.s001 (0.03 MB DOC)

File S2 Annotated multiple species alignments. This file shows the conserved TF binding sites for the different murine and human p110 δ mRNA transcripts as identified by 5' RACE.

Found at: doi:10.1371/journal.pone.0005145.s002 (0.19 MB DOC)

References

1. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, et al. (2001) Synthesis and function of 3-phosphorylated inositol lipids. *Annu Rev Biochem* 70: 535–602.
2. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD (1997) Phosphoinositide 3-kinases: a conserved family of signal transducers. *Trends Biochem Sci* 22: 267–272.
3. Krugmann S, Hawkins PT, Pryer N, Braselmann S (1999) Characterizing the Interactions between the Two Subunits of the p101/p110gamma Phosphoinositide 3-Kinase and Their Role in the Activation of This Enzyme by Gbeta gamma Subunits. *J Biol Chem* 274: 17152–17158.
4. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, et al. (1997) The G[beta][gamma] Sensitivity of a PI3K Is Dependent upon a Tightly Associated Adaptor, p101. *Cell* 89: 105–114.
5. Suire S, Coadwell J, Ferguson GJ, Davidson K, Hawkins P, et al. (2005) p84, a New G[beta][gamma]-Activated Regulatory Subunit of the Type IB Phosphoinositide 3-Kinase p110[gamma]. *Current Biology* 15: 566–570.
6. Voigt P, Dorner MB, Schaefer M (2006) Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. *J Biol Chem* 281: 9977–9986.
7. Guillermet-Guibert J, Bjorklok K, Salpekar A, Gonella C, Ramadani F, et al. (2008) The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. *Proc Natl Acad Sci U S A* 105: 8292–8297.
8. Jia S, Liu Z, Zhang S, Liu P, Zhang L, et al. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. *Nature* 454: 776–779.
9. Cirao E, Iezzi M, Marone R, Marengo S, Curcio C, et al. (2008) Phosphoinositide 3-Kinase p110{beta} Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development. *Sci Signal* 1: ra3.
10. Kok K, Geering B, Vanhaesebroeck B (2008) Regulation of phosphoinositide 3-kinase expression in health and disease. *Trends Biochem Sci* *Accepted for publication*.
11. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL (1999) Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. *J Biol Chem* 274: 10963–10968.
12. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. *Proc Natl Acad Sci U S A* 104: 7809–7814.
13. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, et al. (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. *Proc Natl Acad Sci U S A* 94: 4330–4335.
14. Bi L, Okabe I, Bernard DJ, Nussbaum RL (2002) Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. *Mamm Genome* 13: 169–172.
15. Hu P, Mondino A, Skolnik EY, Schlessinger J (1993) Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. *Mol Cell Biol* 13: 7677–7688.
16. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, et al. (1997) p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. *J Biol Chem* 272: 19236–19241.
17. Eickholt BJ, Ahmed AI, Davies M, Papakonstanti EA, Pearce W, et al. (2007) Control of Axonal Growth and Regeneration of Sensory Neurons by the p110delta PI 3-Kinase. *PLoS ONE* 2: e869.
18. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, et al. (2003) Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. *Cancer Res* 63: 1667–1675.
19. Hirsch E, Wymann MP, Patrucco E, Tolosano E, Bulgarelli-Leva G, et al. (2000) Analysis of the murine phosphoinositide 3-kinase gamma gene. *Gene* 256: 69–81.
20. Barbier M, Attoub S, Calvez R, Laffargue M, Jarry A, et al. (2001) Tumour biology. Weakening link to colorectal cancer? *Nature* 413: 796.
21. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, et al. (2000) Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. *Science* 287: 1046–1049.
22. Alloati G, Marcantoni A, Levi R, Gallo MP, Del Sorbo L, et al. (2005) Phosphoinositide 3-kinase gamma controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. *FEBS Lett* 579: 133–140.
23. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, et al. (2004) PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. *Cell* 118: 375–387.
24. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, et al. (1995) Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. *Science* 269: 690–693.
25. Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS, et al. (2005) The role of endothelial PI3Kgamma activity in neutrophil trafficking. *Blood* 106: 150–157.
26. Li LX, MacDonald PE, Ahn DS, Oudit GY, Backx PH, et al. (2006) Role of phosphatidylinositol 3-kinasegamma in the beta-cell: interactions with glucagon-like peptide-1. *Endocrinology* 147: 3318–3325.
27. MacDonald PE, Joseph JW, Yau D, Diao J, Asghar Z, et al. (2004) Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase. *Endocrinology* 145: 4078–4083.
28. Vecchione C, Patrucco E, Marino G, Barberis L, Poulet R, et al. (2005) Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. *J Exp Med* 201: 1217–1228.
29. Pankow S, Bamberger C, Klippel A, Werner S (2006) Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase. *J Cell Sci* 119: 4033–4046.
30. Ito Y, Sakagami H, Kondo H (1996) Enhanced gene expression for phosphatidylinositol 3-kinase in the hypoglossal motoneurons following axonal crush. *Brain Res Mol Brain Res* 37: 329–332.
31. Okamoto T, Namikawa K, Asano T, Takaoka K, Kiyama H (2004) Differential regulation of the regulatory subunits for phosphatidylinositol 3-kinase in response to motor nerve injury. *Brain Res Mol Brain Res* 131: 119–125.
32. Northcott CA, Hayflick J, Watts SW (2005) Upregulated function of phosphatidylinositol-3-kinase in genetically hypertensive rats: a moderator of arterial hypercontractility. *Clinical and Experimental Pharmacology and Physiology* 32: 851–858.
33. Northcott CA, Hayflick JS, Watts SW (2004) PI3-Kinase Upregulation and Involvement in Spontaneous Tone in Arteries From DOCA-Salt Rats: Is p110{delta} the Culprit? *Hypertension* 43: 885–890.
34. Northcott CA, Poy MN, Najjar SM, Watts SW (2002) Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. *Circ Res* 91: 360–369.
35. Andreelli F, Laville M, Ducluzeau PH, Vega N, Vallier P, et al. (1999) Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients. *Diabetologia* 42: 358–364.
36. Barbour LA, Shao J, Qiao L, Leitner W, Anderson M, et al. (2004) Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. *Endocrinology* 145: 1144–1150.
37. Ducluzeau PH, Perretti N, Laville M, Andreelli F, Vega N, et al. (2001) Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. *Diabetes* 50: 1134–1142.
38. Laville M, Auboeuf D, Khalfallah Y, Vega N, Riou JP, et al. (1996) Acute Regulation by Insulin of Phosphatidylinositol-3-kinase, Rad, Glut 4, and Lipoprotein Lipase mRNA Levels in Human Muscle. *J Clin Invest* 98: 43–49.

Acknowledgments

We dedicate this manuscript to Lizzie Verrall, who initiated this project and who was an inspiration to us all.

We thank Klaus Okkenhaug for his contribution to the early phase of this work, Wim Vanden Berghe for help with the design of the experiments of Figure 2, Dimitri Kioussis for the Vav promoter construct, Sarah Ogilvy for help with the reporter assays and Pedro Cutillas for critically reading the manuscript.

Author Contributions

Conceived and designed the experiments: KK GEN EAGV BV. Performed the experiments: KK GEN EAGV. Analyzed the data: KK GEN EAGV MPP BV. Contributed reagents/materials/analysis tools: DWH MPP. Wrote the paper: KK GEN EAGV MPP BV. Bioinformatic analysis: MPM.

39. Lefai E, Roques M, Vega N, Laville M, Vidal H (2001) Expression of the splice variants of the p85alpha regulatory subunit of phosphoinositide 3-kinase in muscle and adipose tissue of healthy subjects and type 2 diabetic patients. *Biochem J* 360: 117–126.
40. Abell K, Bilancio A, Clarkson RWE, Tiffen PG, Altaparmakov AI, et al. (2005) Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. *Nat Cell Biol* 7: 392–398.
41. Spender LC, Lucchesi W, Bodelon G, Bilancio A, Karstegl CE, et al. (2006) Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. *J Gen Virol* 87: 2859–2867.
42. Kallin A, Johannessen LE, Cani PD, Marbehant CY, Essaghir A, et al. (2007) SREBP1 regulates the expression of heme oxygenase 1 and the phosphatidylinositol-3 kinase regulatory subunit p55gamma. *J Lipid Res* M700136–JLR700200.
43. Park SY, Lee JH, Ha M, Nam JW, Kim VN (2008) miR-29 miRNAs activate p53 by targeting p85alpha and CDC42. *Nat Struct Mol Biol*.
44. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, et al. (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. *Genes Chromosomes Cancer*.
45. Astanache A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, et al. (2008) Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. *J Cell Sci* 121: 664–674.
46. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, et al. (2008) The forkhead transcription factor FOXO3a increases PI3K/Akt activity in drug-resistant leukaemic cells through induction of PIK3CA expression. *Mol Cell Biol*.
47. Yang N, Huang J, Greshock J, Liang S, Barchetti A, et al. (2008) Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. *PLoS ONE* 3: e1758.
48. Baier R, Bondeva T, Klingler R, Bondev A, Wetzker R (1999) Retinoic acid induces selective expression of phosphoinositide 3-kinase gamma in myelomonocytic U937 cells. *Cell Growth Differ* 10: 447–456.
49. Billotet C, Banerjee L, Vanhaesebroeck B, Khwaja A (2009) Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia Without Affecting ATRA-Induced Differentiation. *Cancer Res* 69: 1027–1036.
50. Geiman TM, Robertson KD (2002) Chromatin remodeling, histone modifications, and DNA methylation—how does it all fit together? *J Cell Biochem* 87: 117–125.
51. Jenuwein T, Allis CD (2001) Translating the histone code. *Science* 293: 1074–1080.
52. Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G (1999) The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. *J Biol Chem* 274: 32091–32098.
53. Shestakova E, Bandu MT, Doly J, Bonnefoy E (2001) Inhibition of histone deacetylation induces constitutive derepression of the beta interferon promoter and confers antiviral activity. *J Virol* 75: 3444–3452.
54. Clayton E, McAdam S, Coadwell J, Chantry D, Turner M (2001) Structural organization of the mouse phosphatidylinositol 3-kinase p110delta gene. *Biochem Biophys Res Commun* 280: 1328–1332.
55. Buratowski S (2008) Transcription. Gene expression—where to start? *Science* 322: 1804–1805.
56. Core LJ, Waterfall JJ, Lis JT (2008) Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. *Science* 322: 1845–1848.
57. He Y, Vogelstein B, Velculescu VE, Papadopoulos N, Kinzler KW (2008) The antisense transcriptomes of human cells. *Science* 322: 1855–1857.
58. Preker P, Nielsen J, Kammiller S, Lykke-Andersen S, Christensen MS, et al. (2008) RNA exosome depletion reveals transcription upstream of active human promoters. *Science* 322: 1851–1854.
59. Scila AC, Calabrese JM, Levine SS, Yeo GW, Rahl PB, et al. (2008) Divergent transcription from active promoters. *Science* 322: 1849–1851.
60. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* 447: 799–816.
61. Ogilvy S, Elefanti AG, Visvader J, Bath ML, Harris AW, et al. (1998) Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. *Blood* 91: 419–430.
62. Bories JC, Willerford DM, Grevin D, Davidson L, Camus A, et al. (1995) Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. *Nature* 377: 635–638.
63. Hart A, Melet F, Grossfeld P, Chien K, Jones C, et al. (2000) Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. *Immunity* 13: 167–177.
64. Iwama A, Zhang P, Darlington GJ, McKercher SR, Maki R, et al. (1998) Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPalpha. *Nucleic Acids Res* 26: 3034–3043.
65. Muthusamy N, Barton K, Leiden JM (1995) Defective activation and survival of T cells lacking the Ets-1 transcription factor. *Nature* 377: 639–642.
66. Scott EW, Fisher RC, Olson MC, Kehrl EW, Simon MC, et al. (1997) PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. *Immunity* 6: 437–447.
67. Su GH, Chen HM, Muthusamy N, Garrett-Sinha LA, Baunoch D, et al. (1997) Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B. *EMBO J* 16: 7118–7129.
68. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, et al. (1997) Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. *EMBO J* 16: 4374–4383.
69. Ozato K, Taylor P, Kubota T (2007) The interferon regulatory factor family in host defense: mechanism of action. *J Biol Chem* 282: 20065–20069.
70. Paun A, Pitha PM (2007) The IRF family, revisited. *Biochimie* 89: 744–753.
71. Rao A (1994) NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. *Immunol Today* 15: 274–281.
72. De Boer ML, Mordvinov VA, Thomas MA, Sanderson CJ (1999) Role of nuclear factor of activated T cells (NFAT) in the expression of interleukin-5 and other cytokines involved in the regulation of hemopoietic cells. *Int J Biochem Cell Biol* 31: 1221–1236.
73. Travis A, Amsterdam A, Belanger C, Grosschedl R (1991) LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]. *Genes Dev* 5: 880–894.
74. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, et al. (1992) RAG-1-deficient mice have no mature B and T lymphocytes. *Cell* 68: 869–877.
75. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, et al. (1992) RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. *Cell* 68: 855–867.
76. Jin ZX, Kishi H, Wei XC, Matsuda T, Saito S, et al. (2002) Lymphoid enhancer-binding factor-1 binds and activates the recombination-activating gene-2 promoter together with c-Myb and Pax-5 in immature B cells. *J Immunol* 169: 3783–3792.
77. Brickner AG, Gossage DL, Dusing MR, Wiginton DA (1995) Identification of a murine homolog of the human adenosine deaminase thymic enhancer. *Gene* 167: 261–266.
78. Sawada S, Littman DR (1991) Identification and characterization of a T-cell-specific enhancer adjacent to the murine CD4 gene. *Mol Cell Biol* 11: 5506–5515.
79. Leiden JM, Thompson CB (1994) Transcriptional regulation of T-cell genes during T-cell development. *Curr Opin Immunol* 6: 231–237.
80. Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, et al. (2006) Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. *Proc Natl Acad Sci U S A* 103: 3799–3804.
81. Gebeshuber CA, Sladecsek S, Grunert S (2007) Beta-catenin/LEF-1 signalling in breast cancer—central players activated by a plethora of inputs. *Cells Tissues Organs* 185: 51–60.
82. Hatsell S, Rowlands T, Hiremath M, Cowin P (2003) Beta-catenin and Tcfs in mammary development and cancer. *J Mammary Gland Biol Neoplasia* 8: 145–158.
83. Ravindranath A, O'Connell A, Johnston PG, El-Tanani MK (2008) The role of LEF/TCF factors in neoplastic transformation. *Curr Mol Med* 8: 38–50.
84. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, et al. (2002) Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. *Oncogene* 21: 8506–8509.
85. Furlan A, Vercaemer C, Desbiens X, Poutier A (2008) Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. *J Cell Physiol* 215: 782–793.
86. Buggy Y, Maguire TM, McDermott E, Hill AD, O'Higgins N, et al. (2006) Ets2 transcription factor in normal and neoplastic human breast tissue. *Eur J Cancer* 42: 485–491.
87. Zhang H, Xie X, Zhu X, Zhu J, Hao C, et al. (2005) Stimulatory cross-talk between NFAT3 and estrogen receptor in breast cancer cells. *J Biol Chem* 280: 43188–43197.
88. Teschendorff AE, Journee M, Absil PA, Sepulchre R, Caldas C (2007) Elucidating the altered transcriptional programs in breast cancer using independent component analysis. *PLoS Comput Biol* 3: e161.
89. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, et al. (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. *Science* 297: 1031–1034.
90. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, et al. (2003) The UCSC Genome Browser Database. *Nucleic Acids Res* 31: 51–54.
91. Blanchette M, Kent WJ, Riemer C, Elnitski L, Smit AF, et al. (2004) Aligning multiple genomic sequences with the threaded blockset aligner. *Genome Res* 14: 708–715.
92. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, et al. (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. *Bioinformatics* 21: 2933–2942.
93. Down TA, Hubbard TJ (2002) Computational detection and location of transcription start sites in mammalian genomic DNA. *Genome Res* 12: 458–461.
94. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, et al. (2005) Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. *Genome Res* 15: 1034–1050.